Tag - ANCN

Markets

Ladenburg cuts Anchiano Therapeutics to neutral and removes PT

Ladenburg Thalmann downgraded Anchiano Therapeutics (NASDAQ:ANCN) to “neutral” from “buy” without a price target after the company discontinued its Phase 2 Codex program to focus on its preclinical pan-RAS inhibitor...

November 18, 2019

Markets

Ladenburg starts Anchiano Therapeutics at buy; PT $20

Ladenburg Thalmann initiated coverage of Anchiano Therapeutics (NASDAQ:ANCN) with a “buy” rating and $20 price target. The stock closed at $7.72 on March 8. Anchiano is focused on applying its gene therapy technology as...

March 11, 2019

Tag - ANCN

Ladenburg cuts Anchiano Therapeutics to neutral and removes PT

Ladenburg starts Anchiano Therapeutics at buy; PT $20

General

More